Funding for this research was provided by:
Instituto de Salud Carlos III (PH613883, PI11/00072)
Ministerio de Economía y Competitividad (BFU2015-64408-P, SAF2016-77541-R, BFU2016-80870-P)
European Research Council (311736- PD-HUMMODEL)
Text and Data Mining valid from 2018-02-10
Received: 14 August 2017
Accepted: 7 January 2018
First Online: 10 February 2018
Change Date: 2 April 2018
Change Type: Correction
Change Details: With the author(s)’ decision to opt for Open Choice the copyright of the article changed on March 2018 to © The Author(s) 2018 and the name of one of the author was changed to “Sanjib Guha”.
Compliance with Ethical Standards
: All experiments were performed under the guidelines and protocols of the Ethical Committee for Animal Experimentation (CEEA) of the University of Barcelona. All procedures adhered to internal and EU guidelines for research involving derivation of pluripotent cell lines. All subjects gave informed consent for the study using forms approved by the Ethical Committee on the Use of Human Subjects in Research at Hospital Clinic in Barcelona, Spain. Generation of iPSC lines was approved by the Advisory Committee for Human Tissue and Cell Donation and Use, by the Commission on Guarantees concerning the Donation and Use of Human Tissues and Cells of the Carlos III Health Institute, Madrid, Spain. All procedures were done in accordance with institutional guidelines following the Spanish legislation.
: The authors declare that they have no conflict of interest.